Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph A Dimasi

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Therapeutic Innovation & Regulatory Science|May 21, 2024
New Estimates on the Cost of a Delay Day in Drug DevelopmentZachary P Smith, Joseph A DiMasi, Kenneth A Getz
Journal of Health Economics|February 28, 2003
The price of innovation: new estimates of drug development costsJoseph A DiMasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|March 2, 2016
Innovation in the pharmaceutical industry: New estimates of R&D costsJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
The New England Journal of Medicine|May 14, 2015
The cost of drug developmentJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
American Journal of Therapeutics|May 23, 2007
Mandatory comparator trials for therapeutically similar drugs: an assessment of the factsChristopher-Paul Milne, Kenneth I Kaitin, Joseph A Dimasi
Journal of Health Politics, Policy and Law|March 8, 2008
Misleading congress about drug development: ReplyJoseph A Dimasi, Ronald W Hansen, Henry G Grabowski
Nature Reviews. Drug Discovery|September 13, 2016
Investigating investment in biopharmaceutical R&DPercy H Carter, Ernst R Berndt, Joseph A DiMasi, et al.
Nature Reviews. Drug Discovery|April 14, 2023
Impact of regulatory system changes on the availability of innovative drugs in ChinaQianwei Ge, Lili Xu, Joseph A DiMasi, et al.
Therapeutic Innovation & Regulatory Science|April 23, 2025
Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentJoseph A DiMasi, Melvin Skip Olson, Zachary Smith, et al.
Clinical Pharmacology and Therapeutics|September 11, 2019
Development Times and Approval Success Rates for Drugs to Treat Infectious DiseasesJoseph A DiMasi, Maria I Florez, Stella Stergiopoulos, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Therapeutic Innovation & Regulatory Science|May 21, 2024
New Estimates on the Cost of a Delay Day in Drug DevelopmentZachary P Smith, Joseph A DiMasi, Kenneth A Getz
Journal of Health Economics|February 28, 2003
The price of innovation: new estimates of drug development costsJoseph A DiMasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|March 2, 2016
Innovation in the pharmaceutical industry: New estimates of R&D costsJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
The New England Journal of Medicine|May 14, 2015
The cost of drug developmentJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
American Journal of Therapeutics|May 23, 2007
Mandatory comparator trials for therapeutically similar drugs: an assessment of the factsChristopher-Paul Milne, Kenneth I Kaitin, Joseph A Dimasi
Journal of Health Politics, Policy and Law|March 8, 2008
Misleading congress about drug development: ReplyJoseph A Dimasi, Ronald W Hansen, Henry G Grabowski
Nature Reviews. Drug Discovery|September 13, 2016
Investigating investment in biopharmaceutical R&DPercy H Carter, Ernst R Berndt, Joseph A DiMasi, et al.
Nature Reviews. Drug Discovery|April 14, 2023
Impact of regulatory system changes on the availability of innovative drugs in ChinaQianwei Ge, Lili Xu, Joseph A DiMasi, et al.
Therapeutic Innovation & Regulatory Science|April 23, 2025
Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentJoseph A DiMasi, Melvin Skip Olson, Zachary Smith, et al.
Clinical Pharmacology and Therapeutics|September 11, 2019
Development Times and Approval Success Rates for Drugs to Treat Infectious DiseasesJoseph A DiMasi, Maria I Florez, Stella Stergiopoulos, et al.
Pageof 4